Filing Details

Accession Number:
0001127602-13-024760
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-08 17:01:12
Reporting Period:
2013-08-06
Filing Date:
2013-08-08
Accepted Time:
2013-08-08 17:01:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
850693 Allergan Inc AGN Pharmaceutical Preparations (2834) 951622442
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190642 L Jeffrey Edwards 2525 Dupont Drive
Irvine CA 92612
Evp, Fin & Bus. Dev., Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-08-06 29,200 $58.55 46,071 No 4 M Direct
Common Stock Disposition 2013-08-06 29,200 $91.32 16,871 No 4 S Direct
Common Stock Acquisiton 2013-08-06 40,000 $40.16 56,871 No 4 M Direct
Common Stock Disposition 2013-08-06 40,000 $91.05 16,871 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-08-06 29,200 $0.00 29,200 $58.55
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-08-06 40,000 $0.00 40,000 $40.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-02-02 No 4 M Direct
38,900 2019-02-20 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,006 Indirect By 401(k) Trust
Common Stock 2,660 Indirect By Esop Trust
Footnotes
  1. The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $91.200 to $91.520, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
  2. The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $90.920 to $91.300, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
  3. The option becomes exercisable in four equal annual installments beginning February 2, 2008.
  4. The option became exercisable in four equal annual installments beginning February 20, 2010.